<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03911401</url>
  </required_header>
  <id_info>
    <org_study_id>271-102-00008</org_study_id>
    <nct_id>NCT03911401</nct_id>
  </id_info>
  <brief_title>Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Vehicle Controlled, Parallel-group Comparison Trial to Demonstrate the Superiority of 0.3% and 1% OPA-15406 Ointment to the Vehicle in Pediatric Patients With Atopic Dermatitis (Phase 3 Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the superiority of the investigational medicinal product (IMP; 0.3% OPA-15406
      ointment, 1% OPA-15406 ointment, or vehicle) to the vehicle when administered twice daily for
      4 weeks using success rate in Investigator's Global Assessment (IGA) at Week 4 as the primary
      endpoint in pediatric patients with AD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Actual">December 13, 2019</completion_date>
  <primary_completion_date type="Actual">December 13, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responder rate of Investigator's Global Assesment(IGA) of Disease Severity</measure>
    <time_frame>At Week 4</time_frame>
    <description>The investigator or subinvestigator assesses the skin symptoms using IGA. The investigator or subinvestigator scored the severity (0 = clear, 1 = almost clear, 2 =mild, 3 = moderate, 4 = severe/very severe) of the overall symptoms of the treatment area (erythema, infiltration, papules, effusion and scab formation) at Week 4 . Incidence of success in IGA is defined as the rate of subjects whose IGA score is 0 (clear) or 1 (almost clear) and has improved by at least 2 grades (responders) from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Eczema Area and Severity Index (EASI) Score</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>The investigator or subinvestigator assessed the skin symptoms using EASI. The investigator or subinvestigator scored the severity (0-3 points) and affected BSA (%) based on the 4 symptoms (erythema, infiltration/papules, excoriation, and lichenification) on the 4 body regions (face, neck, and head; upper limbs; trunk; and lower limbs ). The negative value shows the degree of improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Verbal Rating Scale(VRS) for Pruritus Score</measure>
    <time_frame>Baseline, Week 4]</time_frame>
    <description>The investigator or subinvestigator evaluated the pruritus intensity based on VRS. The subjects aged 7 to 14 years old evaluated the pruritus intensity according to the following criteria. The subjects recorded the level of pruritus and the time and date of evaluation in a pruritus diary.
0 : None
: Mild
: Moderate
: Severe For subjects aged 2 to 6 years, this would not be evaluated . The negative value shows the degree of improvement.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">251</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>0.3% OPA-15406</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1% OPA-15406</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3% OPA-15406</intervention_name>
    <description>Twice daily</description>
    <arm_group_label>0.3% OPA-15406</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% OPA-15406</intervention_name>
    <description>Twice daily</description>
    <arm_group_label>1% OPA-15406</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of AD based on the Japanese Dermatological Association's criteria

          -  Atopic dermatitis affecting more than or equal to 5%, to less than or equal to 40% of
             body surface area (BSA, excluding scalp) at the screening and baseline examinations

          -  IGA score of 2 or 3 at the screening and baseline examinations

        Exclusion Criteria:

          -  Subjects who have an AD or contact dermatitis flare-up defined as a rapid
             intensification of AD, within 28 days prior to the baseline examination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osamu Sato</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kato Dermatology Clinic</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 9, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2019</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

